You are viewing the site in preview mode
Skip to main content
|
Studies
|
Study design
|
Total case (n)
|
Population
|
MetS rate
|
MetS definition
|
Follow-up, (years)
|
AF rate
|
|---|
|
Choe-2019
|
Retrospective cohort study
|
22,886,663
|
Korean (aged > 40 years) from the Korean National Health Insurance Service from 2008 to 2013
|
27.4%
|
NCEP-ATPIII
|
5.4
|
0.98%
|
|
Kwon-2019
|
Retrospective cohort study
|
7,830,602
|
Korean (aged 30–69 years) from the Korean National Health Insurance Service from 2009 to 2016
|
15.9%
|
NCEP-ATPIII
|
7.3
|
0.26%
|
|
Kim-2018
|
Prospective cohort study
|
21,981
|
Korean men from a health screening program from 2003 to 2008
|
11.5%
|
International Diabetes Federation
|
8.7
|
0.8%
|
|
Chamberlain-2010
|
Prospective cohort study
|
15,094
|
American (aged 45–64 years) from Atherosclerosis Risk in Communities study from 1987–1989
|
41.1%
|
AHA/NHLBI
|
15.4
|
8.2%
|
|
Nyström-2015
|
Prospective cohort study
|
4,021
|
Stockholmer (aged 60 years) from a health-screening study in Stockholm from August 1997 to March 1999
|
27.6%
|
Other definition standards
|
13.6
|
7.1%
|
|
Watanabe-2008
|
Prospective cohort study
|
28,449
|
Japanese (aged ≥ 20 years) from an annual health examination at the Niigata Association for Comprehensive Health Promotion and Research
|
13% for NCEP-ATPIII; 16% for AHA/NHLBI
|
NCEP-ATPIII or AHA/NHLBI
|
4.5
|
0.9%
|
- Metabolic syndrome = MetS; National Cholesterol Education Program-Third Adult Treatment Panel = NCEP-ATPIII; American Heart Association and National Heart, Lung, and Blood Institute = AHA/NHLBI
